本文選題：膀胱尿路上皮癌 + 抑癌基因�。� 參考：《吉林大學(xué)》2017年碩士論文

【摘要】：目的:通過檢測(cè)TSC1在正常膀胱組織與膀胱膀胱尿路上皮癌組織中的表達(dá)情況,研究TSC1與膀胱膀胱尿路上皮癌的早期診斷、臨床病理以及預(yù)后的關(guān)系。方法:選取膀胱尿路上皮癌組織51例,正常膀胱組織5例。運(yùn)用免疫組化的方法檢測(cè)TSC1在膀胱尿路上皮癌組織和正常膀胱組織中的表達(dá)情況,并結(jié)合患者的臨床資料分析討論TSC1與膀胱尿路上皮癌的關(guān)系。結(jié)果:51例膀胱尿路上皮癌組織中TSC1的陰性表達(dá)率為58.8%,其中非肌層浸潤(rùn)組(Ta-T1)中TSC1的陰性表達(dá)率為52.4%,肌層浸潤(rùn)組(T2-)中TSC1的陰性表達(dá)率為88.9%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。在低分級(jí)組中TSC1的陰性表達(dá)率為44.4%,高分級(jí)組中TSC1的陰性表達(dá)率為75.0%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。術(shù)后隨訪12-36個(gè)月,隨訪的45例膀胱癌患者中其中復(fù)發(fā)者共19人,TSC1在復(fù)發(fā)組中的陰性表達(dá)率為73.7%,在未復(fù)發(fā)組中的陰性表達(dá)率為38.5%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。通過本次實(shí)驗(yàn)我們還發(fā)現(xiàn)TSC1的表達(dá)情況在腫瘤大小、患者性別以及患者年齡方面無(wú)明顯差異(P0.05)。結(jié)論:TSC1在膀胱尿路上皮癌組織中的陰性表達(dá)率明顯高于TSC1在正常膀胱組織中的陰性表達(dá)率,而且TSC1的表達(dá)與膀胱尿路上皮癌的臨床分期、病理分級(jí)以及是否復(fù)發(fā)密切相關(guān)�？捎糜诎螂装┑脑缙谠\斷、臨床分期、病理分級(jí)及預(yù)后評(píng)估。
[Abstract]:Objective: to study the relationship between TSC1 and bladder urothelial carcinoma in early diagnosis, clinicopathology and prognosis by detecting the expression of TSC1 in normal bladder and bladder urothelial carcinoma.Methods: 51 cases of bladder urothelial carcinoma and 5 cases of normal bladder were selected.Immunohistochemical method was used to detect the expression of TSC1 in bladder urothelial carcinoma and normal bladder tissue. The relationship between TSC1 and bladder urothelial carcinoma was discussed in combination with the clinical data of the patients.Results the negative expression rate of TSC1 was 58.8% in 51 cases of bladder urothelial carcinoma, including 52.4% in non-myometrial infiltration group (Ta-T1) and 88.9% in musculocutaneous infiltration group (P 0.05).In the low grade group, the negative expression rate of TSC1 was 44.4, and the negative expression rate of TSC1 in the high grade group was 75.05.The difference was statistically significant (P 0.05).The negative expression rate of TSC1 was 73.7 in the recurrent group and 38.5 in the non-recurrence group. The difference was statistically significant (P 0.05).We also found that there was no significant difference in the expression of TSC1 in tumor size, patient sex and patient age.Conclusion the negative expression rate of TSC1 in bladder urothelial carcinoma is significantly higher than that of TSC1 in normal bladder tissue, and the expression of TSC1 is closely related to the clinical stage, pathological grade and recurrence of bladder urothelial carcinoma.It can be used for early diagnosis, clinical stage, pathological grade and prognosis evaluation of bladder cancer.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.14

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 張璐琪;李曉鳳;;TSC基因與腫瘤轉(zhuǎn)移相關(guān)性的研究進(jìn)展[J];內(nèi)蒙古醫(yī)學(xué)雜志;2014年04期

2 程魯京,蘭風(fēng)華;結(jié)節(jié)性硬化癥分子生物學(xué)研究進(jìn)展[J];國(guó)外醫(yī)學(xué).遺傳學(xué)分冊(cè);2005年05期

，

本文編號(hào)：1759901